A review of clinical trials of therapies for osteoporosis using fracture as an end point

Journal of Clinical Densitometry

Volumn 2, Issue 4, 1999, Pages 435-452

  Blank, Robert D ^a   Bockman, Richard S ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NONE

Author keywords

Aging; Bone; Clinical trials; Fractures (prevention and control); Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; FLUORIDE SODIUM; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; FRACTURE; HUMAN; MALE; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS;

CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SODIUM FLUORIDE; VITAMIN D;

EID: 0033254196     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-6950(06)60409-5     Document Type: Review

References (71)

1. Schneider EL, Guralnik JM. 1990 The aging of America: impact on health care costs. JAMA 263:2335-2340.
2. Chrischilles EA, Butler CD, Davis CS, Wallace RB. 1991 A model of lifetime osteoporosis impact. Arch Intern Med 151:2026-2032.
3. 1997 Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1-6.
4. 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1-129.
5. Wasnich R. 1993 Bone mass measurement: prediction of risk. Am J Med 95:6S-10S.
6. Svirbely JR, Sriram MG. 1999 The Medical Algorithms Project. Chapter 39.13.4 Confidence Interval for the Difference Between Two Proportions Based on the Odds Ratio, 〈http://www.medal.org/index.html〉. Version 3.0.
7. Canalis E. 1996 Regulation of Bone Remodeling. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Favus MJ, ed. 3rd ed. Lippincott-Raven, Philadelphia, 29-35.
8. Heaney RP. 1994 The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9:1515-1523.
9. Karpf DB, Shapiro DR, Seeman E, et al. 1997 Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277:1159-1164.
10. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. 1995 Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98:331-335.
11. Recker RR, Hinders S, Davies KM, et al. 1996 Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11:1961-1966.
12. Chevalley T, Rizzoli R, Nydegger V, et al. 1994 Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 4:245-252.
13. Cumming RG, Nevitt MC. 1997 Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 12:1321-1329.
14. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. 1996 Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 124:400-406.
15. Chapuy MC, Arlot ME, Duboeuf F, et al. 1992 Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642.
16. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670-676.
17. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL. 1995 Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 61:1140-1145.
18. Orimo H, Shiraki M, Hayashi Y, et al. 1994 Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370-376.
19. Gallagher JC, Riggs BL. 1990 Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 39:30-34.
20. Gallagher JC, Goldgar D. 1990 Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: a randomized controlled study. Ann Intern Med 113:649-655.
21. Tilyard MW, Spears GF, Thomson J, Dovey S. 1992 Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362.
22. Orimo H, Shiraki M, Hayashi T, Nakamura T. 1987 Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner 3:47-52.
23. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F. 1992 Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131-138.
24. Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M. 1995 Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 56:181-185.
25. Overgaard K, Hansen MA, Jensen SB, Christiansen C. 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556-561.
26. Stock JL, Avioli LV, Baylink DJ, et al. 1997 Calcitoninsalmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: 3 year interim results of the PROOF study. J Bone Miner Res 12:S149.
27. Silverman SL, Chesnut C, Andriano K, et al. 1998 Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF study. Bone 23:S174.
28. Fleisch H. 1991 Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944.
29. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
30. Watts NB, Harris ST, Genant HK, et al. 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
31. Harris ST, Watts NB, Jackson RD, et al. 1993 Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567.
32. Chesnut CH III, McClung MR, Ensrud KE, et al. 1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
33. Liberman UA, Weiss SR, Broll J, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
34. Black DM, Cummings SR, Karpf DB, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
35. Ensrud KE, Black DM, Palermo L, et al. 1997 Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157:2617-2624.
36. Cummings SR, Black DM, Thompson DE, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082.
37. Hosking D, Chilvers CED, Christiansen C, et al. 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492.
38. Pols HA for the FOSIT study group. 1997 A multinational, placebo-controlled study of alendronate in post menopausal women with osteoporosis - results from the FOSIT study. J Bone Miner Res 12(Suppl. 1), p. S172.
39. Lindsay R, Hart DM, Forrest C. Baird C. 1980 Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151-1154.
40. Lufkin EG, Wahner HW, O'Fallon WM, et al. 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9.
41. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. 1980 Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198.
42. Johnson RE, Specht EE. 1981 The risk of hip fracture in postmenopausal females with or without estrogen drug exposure. Am J Public Health 71:138-144.
43. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. 1981 Menopausal estrogen therapy and hip fractures. Ann Intern Med 95:28-31.
44. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. 1987 Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 317:1169-1174.
45. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. 1995 Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 122:9-16.
46. Maxim P, Ettinger B, Spitalny GM. 1995 Fracture protection provided by long-term estrogen treatment. Osteoporos Int 5:23-29.
47. Ensrud K, Black D, Recker R, et al. 1998 The effect of 2 and 3 years of Raloxifene on vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Bone 23:S174.
48. Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. 1982 Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 306:446-450.
49. Mamelle N, Meunier PJ, Dusan R, et al. 1988 Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365.
50. Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. 1989 Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 68:150-159.
51. Pak CY, Sakhaee K, Zerwekh JE. 1990 Effect of intermittent therapy with a slow-release fluoride preparation. J Bone Miner Res 1(Suppl. 5):S149-S155.
52. Pak CY, Sakhaee K, Piziak V, et al. 1994 Slow-release sodium fluoride in the management of postmenopausal osteoporosis: a randomized controlled trial. Ann Intern Med 120:625-632.
53. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. 1995 Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 123:401-408.
54. Hansson T, Roos B. 1987 The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 40:315-317.
55. Hedlund LR, Gallagher JC. 1989 Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res 4:223-225.
56. Riggs BL, Hodgson SF, O'Fallon WM, et al. 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809.
57. Kleerekoper M, Peterson EL, Nelson DA, et al. 1991 A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1:155-161.
58. Eastell R. 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746.
59. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709.
60. Reeve J, Meunier PJ, Parsons JA, et al. 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280:1340-1344.
61. Slovik DM, Neer RM, Potts JT Jr. 1981 Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 68:1261-1271.
62. Tam CS, Heersche JN, Murray TM, Parsons JA. 1982 Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506-512.
63. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM. 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-1148.
64. Lindsay R, Nieves J, Formica C, et al. 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
65. Ross PD, Davis JW, Epstein RS, Wasnich RD. 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923.
66. Ross PD, Davis JW, Wasnich RD. 1993 Bone mass and beyond: risk factors for fractures. Calcif Tissue Int 53(Suppl. 1):S134-S137; discussion S137, S138.
67. Cummings SR, Nevitt MC, Browner WS, et al. 1995 Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773.
68. Cummings SR. 1996 Treatable and unbeatable risk factors for hip fracture. Bone 18:165S-167S.
69. Ross PD. 1996 Prediction of fracture risk. II: Other risk factors. Am J Med Sci 312:260-269.
70. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJD. 1992 Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227.
71. Nevitt MC, Ettinger B, Black DM, et al. 1998 The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793-800.